Delian Capital leads Series A round for OnKure
OnKure Inc, an epigenetics-focused drug discovery and development company, has secured $7 million in Series A financing. Delian Capital led the round.
3 May 2018•1 min read
OnKure Inc, an epigenetics-focused drug discovery and development company, has secured $7 million in Series A financing. Delian Capital led the round.
